ProspectiveMaleAYA - Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors

In the past two decades, knowledge regarding the gonadotoxicity of cancer treatments and their impact on fertility and pregnancy outcomes has expanded. However, prospective, standardized, longitudinal data remain largely unavailable, particularly for:

* long-term endocrine and reproductive outcomes, * effects of novel systemic therapies (e.g., immunotherapy, targeted therapies)

To address this gap, we will conduct a prospective, multicentre, longitudinal cohort study (ProspectiveMaleAYA cohort) in adolescent and young adult (AYA) male cancer patients.

Participants will be enrolled for this study after having received a diagnosis of primary cancer (no relapse or secondary cancers) and if they will receive or are already receiving oncological treatment. Clinical, oncologic, reproductive, endocrine, biological and patient-reported data will be collected at predefined follow-up intervals. Substudies including analyses of biological materials will be conducted in sub-cohorts.

The study aims to harmonize data collection across participating European centres and to set up a large-scale network structure of emerging data collection programmes to evaluate the gonadotoxic risk, including the prevalence and course of testicular dysfunction and/or fertility impairment and oligo/azoospermia following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. In addition to clinical information, whole genome sequencing data will be generated for selected individuals with evidence of varying impact of gonadotoxic therapies on reproductive function. The aim is to find genetic variants associated with risk of reproductive and organ toxicity, and to build and enhance individual predictive risk models for gonadotoxic therapies. Additionally, data on sexual health, quality of life and subjective health status shall be analysed to support patient-centric care.

The objectives of this prospective analysis of European adolescent and young adult (AYA) cancer patient cohorts are:

* Establish harmonized prospective databases with relevant clinical characteristics at time of diagnosis, cancer therapy received and post-cancer clinical and reproductive outcomes by following AYA cancer patients longitudinally. * Evaluate the impact of cancer treatment on long-term fertility according to cancer type, patient characteristics (pre- and post-treatment) and treatment modalities in a male AYA population * Establish predictive parameters for the recovery of spermatogenesis and for the later development of hypogonadism * Classification of patients into low-, medium- and high-risk groups for the development of hypogonadism and infertility.

For specific sub-cohorts, the following objectives are planned:

* Sub-cohort 1: Determine the duration of genetic/epigenetic alterations in spermatozoa to define the minimum time-period after AYA cancer treatment to attempt safe conception. * Sub-cohort 2: i) To set up a genetic database based on whole genome sequencing of AYAs of the cohort; ii) To evaluate the role of genetic background on determining persistent damage to testicular function (reproductive and endocrine); iii) To develop prediction models for organ toxicities in cancer patients. * Sub-cohort 3: i) To test and evaluate the magnitude of accelerated aging following oncological treatments BEP (testicular cancer) or ABVD (Hodgkin lymphoma) through epigenetic clock and mosaic Y chromosome loss (mLoY); ii) To assess the role of clinical and the genetic factors in accelerated aging following oncological treatments. * Sub-cohort 4: Evaluate the frequency and entity of sexual health dysfunctions in male cancer survivors, according to the disease and treatment. * Sub-cohort 5: Mapping access and barriers to reproductive counseling and FP, and evaluating the satisfaction with these programs.

• Frequency of severe sperm DNA fragmentation according to the type of cancer treatment at different time points (pre- and post-therapy) [Срок оценки: June 2030]
• Frequency of alterations in sperm DNA methylation (target genes) [Срок оценки: June 2030]
• Whole-genome sequencing database including data from subset of patients [Срок оценки: June 2030]
• Database of validated genetic loci and associated with risk of persistent azoo/oligozoospermia and hypogonadism [Срок оценки: June 2030]
• Validated risk prediction models for chemotherapy induced effects on testicular function pre-post cancer treatment in relation to cancer diagnosis and therapy [Срок оценки: June 2030]
• Epigenetic clock variations in males following oncological treatments [Срок оценки: June 2030]
• Frequency of Y chromosome loss (mLoY) in males following oncological treatments [Срок оценки: June 2030]
• Evaluate the general quality of life in male cancer survivors, according to the disease and treatment using the validated questionnaire EORTC-qlq-c30. [Срок оценки: June 2030]
• Examine decision-making and fertility procedures with anonymous survey to capture lived experiences among AYA cancer survivors. [Срок оценки: June 2028]
• Evaluate the frequency and entity of sexual health dysfunctions in male cancer survivors, according to the disease and treatment using the validated questionnaire EORTC-SH22. [Срок оценки: June 2030]
• Examine decision-making and fertility communications with an anonymous survey to capture lived experiences among AYA cancer HCPs. [Срок оценки: June 2028]
• Examine unmet needs and service gaps with a qualitative interview to capture lived experiences among AYA cancer survivors. [Срок оценки: June 2028]